Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Business Wire
Covered in this story
Analyst targets on Verastem Inc
- BTIG: $7.97 → $18 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $VSTM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Verastem Inc →Summary aggregated from Business Wire's public RSS feed. The full reporting belongs to Business Wire — please read it on their site.